Andrew Combs insider trades: Prelude Therapeutics (PRLD) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Andrew reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 25, 2025 | PRLD | ↑ Buy | 100,000 | $0.69 | $69K | Direct | Mar 27, 2025 (2d) |
| Dec 23, 2024 | PRLD | ↑ Buy | 63,075 | $1.36 | $86K | Direct | Dec 26, 2024 (3d) |
| Dec 14, 2021 | PRLD | ↑ Buy | 8,000 | $11.86 | $95K | Direct | Dec 15, 2021 (1d) |
| Sep 29, 2020 | PRLD | ↑ Buy | 1,000 | $19.00 | $19K | Direct | Sep 29, 2020 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Andrew Combs's insider trades
Andrew Combs is Chief Chemistry Officer at Prelude Therapeutics (PRLD). Since Sep 29, 2020, Andrew has reported 4 open-market purchases worth $269K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (6 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PRLD insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.